Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen , Hall, Peter, Mansi, Janine , Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David , Cameron , David and Wardley, Andrew (2020) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology . doi:10.1016/j.clon.2020.07.006 (In Press)

PDF WRAP-optimising-duration-adjuvant-trastuzumab-early-breast-cancer-UK-Hiller-2020.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only until 25 July 2021. Contact author directly, specifying your specific needs. - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (1205Kb)

Request Changes to record.

Abstract

Adjuvant trastuzumab for patients with HER2-positive early breast cancer showed significant improvements in both disease-free and overall survival with 12 months of treatment [1,2], which was approved by the National Institute for Health and Care Excellence (NICE) in the UK in 2006. When the FinHer trial showed similar results with 9 weeks of trastuzumab [3], there was significant interest in whether shorter durations might be as effective. Additional benefits for patients could be less toxicity, fewer hospital visits and a more rapid return to normal life, with considerable societal benefits of reduced costs. PERSEPHONE was the pragmatic UK duration trial funded by the National Institute for Health Research, Health Technology Assessment Programme (NIHR HTA), which showed that 6 months of adjuvant trastuzumab was non-inferior to 12 months with a 4-year disease-free survival rate of 89.4% compared with 89.8% (non-inferiority P = 0.01) [4]. Less toxicity was reported with 6 months, particularly cardiac toxicity, and there were cost savings over the first 2 years [5], which were maintained over an average patient's lifetime when extrapolated using an economic model. After the publication of these results in June 2019, the Optimal Duration of Adjuvant Trastuzumab Working Group was convened, comprising a diverse, multidisciplinary membership. There were representatives from the PERSEPHONE Trial Management Group, including patient advocates, the National Cancer Research Institute (NCRI) Breast Group, the Association of Cancer Physicians, the Royal College of Radiologists and the Independent Cancer Patients' Voice. By November 2019, both dual antibody treatment with trastuzumab and pertuzumab [6] and extended neratinib after single-agent trastuzumab [7] had been approved by NICE, only for those at high risk of recurrence. Therefore, single-agent trastuzumab remained standard of care for those at lower risk of recurrence and recommendations were made for these patients.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Trastuzumab, Breast -- Cancer -- Adjuvant treatment -- Great Britain, Breast -- Cancer -- Chemotherapy, Cancer -- Gene therapy
Journal or Publication Title:	Clinical Oncology
Publisher:	Elsevier B.V.
ISSN:	0936-6555
Official Date:	2020
Dates:	Date Event 2020 Published 25 July 2020 Available 23 June 2020 Accepted
Date of first compliant deposit:	20 July 2020
DOI:	10.1016/j.clon.2020.07.006
Status:	Peer Reviewed
Publication Status:	In Press
Access rights to Published version:	Restricted or Subscription Access
Copyright Holders:	© 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Related URLs:	Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item